Taltz is a humanized interleukin-17A antagonist indicated for the treatment of moderate to severe plaque psoriasis. It is also indicated for active psoriatic arthritis. This product comes supplied in a prefilled autoinjector. The manufacturer of this product is Eli Lilly, a pharmaceutical company.
What is it made of?
Taltz contains the active ingredient ixekizumab. It is produced by recombinant deoxyribonucleic acid (DNA) technology. The solution of this product is clear and colorless to slightly yellow.
What are its uses?
Taltz is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is also indicated for active psoriatic arthritis in adult patients.
How long do its effects last?
The elimination half-life of Taltz has been shown to be thirteen days.